CD8A and breast cancer: IPA then reprograms CD8+ T-cell stemness by promoting H3K27 acetylation at Tcf7 superenhancers to facilitate the generation of progenitor exhausted CD8+ T cells, thereby augmenting the antitumor immune response against melanoma, breast cancer, and colorectal cancer.